Cubist and Teva Resolve Dispute

Cubist Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. (TEVA) have resolved their dispute by Cubist agreeing to license its antibiotic Cubicin to Teva . Under the agreement Teva can start selling its generic version in June 2018 if Cubist is granted a six-month extension of marketing protection for pediatric use.

The patent is due to expire in September 2019. Without pediatric clearance, Teva may sell Cubicin starting in December 2017.

The case: Cubist Pharmaceuticals Inc. (CBST), v. Teva Parenteral Medicines Inc., 1:09-cv-00189-GMS, U.S. District Court, District of Delaware (Wilmington).



Categories: drugs, infringement, Licensing, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, Teva

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: